Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2023-04-13 Annual Report
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'Ascelia Pharma Årsredovisning 2022', which translates to 'Annual Report 2022'. It contains detailed sections typical of an annual report, including CEO letter (VD-ORD), key events during the year, strategy, product portfolio, financial information, risk management, corporate governance report, board and management information, notes, and audit report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive business overview, financial position, clinical study updates, and outlook, all consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-13 Swedish
KALLELSE TILL ÅRSSTÄMMA I ASCELIA PHARMA AB
AGM Information Classification · 100% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I ASCELIA PHARMA AB" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB". It details the date, time, location, registration procedures, proxy rules, and the proposed agenda for the meeting. The agenda items (e.g., election of chairman, approval of the annual report, decisions on profit distribution, election of board members, remuneration, and authorization for share issues) are characteristic of an Annual General Meeting (AGM). Although it contains proposals that might be found in other reports (like remuneration and financial results context), the primary purpose and structure of the document is the formal notice and agenda for the AGM. Therefore, the correct classification is AGM-R.
2023-04-03 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB
AGM Information Classification · 100% confidence The document is explicitly titled 'NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB' and details the date, location, procedures for shareholder participation, proxies, and the proposed agenda for the meeting. The agenda items cover the election of the chairman, approval of reports, determination of board/auditor remuneration, and resolutions on share authorizations and incentive programs. This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2023-04-03 English
Ascelia Pharma Mourns the Passing of Board Member René Spogárd
Board/Management Information Classification · 99% confidence The document is a short announcement dated March 13, 2023, titled "Ascelia Pharma Mourns the Passing of Board Member René Spogárd." The core content is the notification of the death of a board member and includes condolences and background information on the company and its products. This directly relates to a change in the company's board of directors/senior management. This aligns perfectly with the definition for Board/Management Information (MANG). The document length is short (3070 chars), but it is the primary announcement itself, not an announcement *about* a report, so the RPA/RNS rule does not apply here.
2023-03-13 English
Ascelia Pharma sörjer styrelseledamot René Spogárds bortgång
Board/Management Information Classification · 98% confidence The document is a short announcement dated March 13, 2023, stating that a board member, René Spogárd, has passed away. It includes quotes from the Chairman and contact information for the CEO and CFO/IR. This content directly relates to a change in the company's board of directors/senior management composition. This aligns perfectly with the definition for Board/Management Information (MANG). The document length is short (3010 chars) and it is an announcement, not a comprehensive report.
2023-03-13 Swedish
Change in number of shares and votes in Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly details a 'Change in number of shares and votes' due to the conversion of series C shares into ordinary shares related to a performance-based share saving program. This action directly impacts the company's capital structure and outstanding shares. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA), which covers changes in capital structure, including share counts. Although it is a short announcement, the core content is the capital change itself, not just an announcement of a report, making SHA more specific than RPA or RNS. The document is not a general regulatory filing (RNS) because it fits a specific category.
2023-02-28 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.